Effects of matrix metalloproteinase-9 and tissue inhibitor-1 of metalloproteinase expression on atrial structural remodeling during chronic atrial fibrillation

National Medical Journal of China

Volumn 85, Issue 1, 2005, Pages 45-48

  Zhu, Hui ^a   Zhang, Wei ^b   Guo, Chen Hong ^b   Zhang, Gong ^b   Zhang, Wei Dong ^b   Zhong, Ming ^b   Yang, Gui Rong ^b   Ge, Zhi Ming ^b   Zhang, Yun ^b  

^a SHANDONG UNIVERSITY   (China)

^b NONE

Author keywords

Atrial fibrillation; Immunologic; Matrix metalloproteinases; Metalloproteinases; Suppressor factors

Indexed keywords

GELATINASE B; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AORTA VALVE REPLACEMENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DOWN REGULATION; FEMALE; HEART ATRIUM APPENDAGE; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART MUSCLE BIOPSY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MITRAL VALVE REPLACEMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINUS RHYTHM; STATISTICAL SIGNIFICANCE; TRANSTHORACIC ECHOCARDIOGRAPHY; UPREGULATION;

ADULT; ATRIAL FIBRILLATION; ATRIAL FUNCTION; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 13844255016     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Spinale FG, Coker ML, Bond BR, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart : a potential therapeutic target. Cardilvasc Res, 2000, 46:225-238.
2. Saharinen J, Hyytiainen M, Taipale J, et al. Latent transforming growth factor-beta binding proteins ( LTBPs ) - structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev, 1999, 10: 99-117.
3. Peterson JT, Li H, Dillon L, et al. Evolution of matrix metalloproteinase and tissue inhibitor expression during heart failure progression int infracted rat. Cardiovasc Res, 2000, 46:307-315.
4. Nagahiro N, Kazuhiro Y, Yasushi S, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res, 2003, 57:766-774.
5. Ducharme A ,Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest, 2000, 106:55-62.
6. Heymans S,Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metallproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure . Nat Med, 1999, 5:1135-1142.
7. Borg TK, Burgess ML. Holding it all together: organization and function( s ) of the extracellular matrix of the heart. Heart Failure, 1993,8: 230-238.
8. Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation, 1998, 98:1728-1734.
9. Roten L, Nemoto S, Simsic J, et al. Effects of gene diletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol, 2000, 32:109-120.